@entity1600 ( @entity1600 ) is widely employed to detect axillary lymph node @entity3 in @entity0 @entity1 with clinically negative (N0) axillae. One of the few reported contraindications to @entity1600 is prior treatment with systemic chemotherapy (neoadjuvant/induction chemotherapy). Previous investigators reported difficulty identifying the sentinel node and an unacceptable false-negative rate in this @entity1 cohort. We present one experienced surgeon's experience with @entity1600 following induction chemotherapy (n = 21). Following treatment with @entity632 and Cytoxan (AC)-based cyclic chemotherapy, @entity1 underwent @entity1600 , followed by levels I and II axillary lymph node dissection (ALND). At least one sentinel node was identified in all @entity1 (100%). With respect to @entity3 , the status of the sentinel node(s) accurately reflected the status of the axilla in 20 of 21 @entity1 (95%). Eleven @entity1 (52%) had axillary @entity3 identified by ALND. Of this group, @entity1600 failed to identify @entity3 in one @entity1 (9%). Previous treatment with induction chemotherapy should not be considered an absolute contraindication to @entity1600 . An experienced surgeon may utilize the technique in these @entity1 , sparing them the added morbidity of axillary dissection.

Accuracy of axillary sentinel lymph node biopsy following neoadjuvant (induction) chemotherapy for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity632 :: ('MESH:D004317', 'Chemical') :: ['Adriamycin'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity1600 :: ('MESH:D014388', 'Disease') :: ['SLNB', 'Sentinel lymph node biopsy'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases', 'metastatic disease']
@entity0 :: (MESH:D001943,Disease) :: ['carcinoma of the breast']
